Effectiveness of third-class biologic treatment in crohn’s disease: A multi-center retrospective cohort study

Ahmad Albshesh; Joshua Taylor; Edoardo V. Savarino; Marie Truyens; Alessandro Armuzzi; Davide G. Ribaldone; Ariella Bar Gil Shitrit; Morine Fibelman; Pauliina Molander; Claire Liefferinckx; Stephane Nancey; Mohamed Korani; Mariann Rutka; Manuel Barreiro De Acosta; Viktor Domislovic; Gerard Suris; Carl Eriksson; Catarina Alves; Afroditi Mpitouli; Caroline Di Jiang; Katja Tepeš; Marina Coletta; Kalliopi Foteinogiannopoulou; Javier P. Gisbert; Hadar Amir-Barak; Mohamed Attauabi; Jakob Seidelin; Waqqas Afif; Carla Marinelli; Triana Lobaton; Daniela Pugliese; Nitsan Maharshak; Anneline Cremer; Jimmy K. Limdi; Tamás Molnár; Borja Otero-Alvarin; Zeljko Krznaric; Fernando Magro; Konstantinos Karmiris; Tim Raine; David Drobne; Ioannis Koutroubakis; Maria Chaparro; Henit Yanai; Johan Burisch; Uri Kopylov

doi:10.3390/jcm10132914

Effectiveness of third-class biologic treatment in crohn’s disease: A multi-center retrospective cohort study

Ahmad Albshesh^*, Joshua Taylor, Edoardo V. Savarino, Marie Truyens, Alessandro Armuzzi, Davide G. Ribaldone, Ariella Bar Gil Shitrit, Morine Fibelman, Pauliina Molander, Claire Liefferinckx, Stephane Nancey, Mohamed Korani, Mariann Rutka, Manuel Barreiro De Acosta, Viktor Domislovic, Gerard Suris, Carl Eriksson, Catarina Alves, Afroditi Mpitouli, Caroline Di JiangKatja Tepeš, Marina Coletta, Kalliopi Foteinogiannopoulou, Javier P. Gisbert, Hadar Amir-Barak, Mohamed Attauabi, Jakob Seidelin, Waqqas Afif, Carla Marinelli, Triana Lobaton, Daniela Pugliese, Nitsan Maharshak, Anneline Cremer, Jimmy K. Limdi, Tamás Molnár, Borja Otero-Alvarin, Zeljko Krznaric, Fernando Magro, Konstantinos Karmiris, Tim Raine, David Drobne, Ioannis Koutroubakis, Maria Chaparro, Henit Yanai, Johan Burisch, Uri Kopylov

^*Corresponding author for this work

Internal Medicine

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn’s disease (CD) failing anti-Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD. Results: Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second-and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second-and VDZ as a third-class therapy (group B). At week 16–22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (p = 0.9); 41/156 (26.2%) and 15/48 (31.2%) were in clinical remission (p = 0.5). At week 52; 89/103 (86%) patients and 25/29 (86.2%) of the patients with available data had responded to third-class treatment in groups A and B, respectively (p = 0.9); 31/103 (30%) and 47/29 (24.1%) were in clinical remission (p = 0.5). Conclusion: Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent.

Original language	English
Article number	2914
Journal	Journal of Clinical Medicine
Volume	10
Issue number	13
DOIs	https://doi.org/10.3390/jcm10132914
State	Published - 1 Jul 2021

Keywords

Anti-TNF failure
Crohn’s disease
Treatment failure
Treatment response
Ustekinumab
Vedolizumab

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/jcm10132914

Cite this

Albshesh, A., Taylor, J., Savarino, E. V., Truyens, M., Armuzzi, A., Ribaldone, D. G., Shitrit, A. B. G., Fibelman, M., Molander, P., Liefferinckx, C., Nancey, S., Korani, M., Rutka, M., Acosta, M. B. D., Domislovic, V., Suris, G., Eriksson, C., Alves, C., Mpitouli, A., ... Kopylov, U. (2021). Effectiveness of third-class biologic treatment in crohn’s disease: A multi-center retrospective cohort study. Journal of Clinical Medicine, 10(13), Article 2914. https://doi.org/10.3390/jcm10132914

@article{aea02369ee0d4d06afb83aedd32bf62b,

title = "Effectiveness of third-class biologic treatment in crohn{\textquoteright}s disease: A multi-center retrospective cohort study",

abstract = "Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn{\textquoteright}s disease (CD) failing anti-Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD. Results: Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second-and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second-and VDZ as a third-class therapy (group B). At week 16–22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (p = 0.9); 41/156 (26.2%) and 15/48 (31.2%) were in clinical remission (p = 0.5). At week 52; 89/103 (86%) patients and 25/29 (86.2%) of the patients with available data had responded to third-class treatment in groups A and B, respectively (p = 0.9); 31/103 (30%) and 47/29 (24.1%) were in clinical remission (p = 0.5). Conclusion: Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent.",

keywords = "Anti-TNF failure, Crohn{\textquoteright}s disease, Treatment failure, Treatment response, Ustekinumab, Vedolizumab",

author = "Ahmad Albshesh and Joshua Taylor and Savarino, {Edoardo V.} and Marie Truyens and Alessandro Armuzzi and Ribaldone, {Davide G.} and Shitrit, {Ariella Bar Gil} and Morine Fibelman and Pauliina Molander and Claire Liefferinckx and Stephane Nancey and Mohamed Korani and Mariann Rutka and Acosta, {Manuel Barreiro De} and Viktor Domislovic and Gerard Suris and Carl Eriksson and Catarina Alves and Afroditi Mpitouli and {Di Jiang}, Caroline and Katja Tepe{\v s} and Marina Coletta and Kalliopi Foteinogiannopoulou and Gisbert, {Javier P.} and Hadar Amir-Barak and Mohamed Attauabi and Jakob Seidelin and Waqqas Afif and Carla Marinelli and Triana Lobaton and Daniela Pugliese and Nitsan Maharshak and Anneline Cremer and Limdi, {Jimmy K.} and Tam{\'a}s Moln{\'a}r and Borja Otero-Alvarin and Zeljko Krznaric and Fernando Magro and Konstantinos Karmiris and Tim Raine and David Drobne and Ioannis Koutroubakis and Maria Chaparro and Henit Yanai and Johan Burisch and Uri Kopylov",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = jul,

day = "1",

doi = "10.3390/jcm10132914",

language = "אנגלית",

volume = "10",

journal = "Journal of Clinical Medicine",

issn = "2077-0383",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "13",

}

Albshesh, A, Taylor, J, Savarino, EV, Truyens, M, Armuzzi, A, Ribaldone, DG, Shitrit, ABG, Fibelman, M, Molander, P, Liefferinckx, C, Nancey, S, Korani, M, Rutka, M, Acosta, MBD, Domislovic, V, Suris, G, Eriksson, C, Alves, C, Mpitouli, A, Di Jiang, C, Tepeš, K, Coletta, M, Foteinogiannopoulou, K, Gisbert, JP, Amir-Barak, H, Attauabi, M, Seidelin, J, Afif, W, Marinelli, C, Lobaton, T, Pugliese, D, Maharshak, N, Cremer, A, Limdi, JK, Molnár, T, Otero-Alvarin, B, Krznaric, Z, Magro, F, Karmiris, K, Raine, T, Drobne, D, Koutroubakis, I, Chaparro, M, Yanai, H, Burisch, J & Kopylov, U 2021, 'Effectiveness of third-class biologic treatment in crohn’s disease: A multi-center retrospective cohort study', Journal of Clinical Medicine, vol. 10, no. 13, 2914. https://doi.org/10.3390/jcm10132914

TY - JOUR

T1 - Effectiveness of third-class biologic treatment in crohn’s disease

T2 - A multi-center retrospective cohort study

AU - Albshesh, Ahmad

AU - Taylor, Joshua

AU - Savarino, Edoardo V.

AU - Truyens, Marie

AU - Armuzzi, Alessandro

AU - Ribaldone, Davide G.

AU - Shitrit, Ariella Bar Gil

AU - Fibelman, Morine

AU - Molander, Pauliina

AU - Liefferinckx, Claire

AU - Nancey, Stephane

AU - Korani, Mohamed

AU - Rutka, Mariann

AU - Acosta, Manuel Barreiro De

AU - Domislovic, Viktor

AU - Suris, Gerard

AU - Eriksson, Carl

AU - Alves, Catarina

AU - Mpitouli, Afroditi

AU - Di Jiang, Caroline

AU - Tepeš, Katja

AU - Coletta, Marina

AU - Foteinogiannopoulou, Kalliopi

AU - Gisbert, Javier P.

AU - Amir-Barak, Hadar

AU - Attauabi, Mohamed

AU - Seidelin, Jakob

AU - Afif, Waqqas

AU - Marinelli, Carla

AU - Lobaton, Triana

AU - Pugliese, Daniela

AU - Maharshak, Nitsan

AU - Cremer, Anneline

AU - Limdi, Jimmy K.

AU - Molnár, Tamás

AU - Otero-Alvarin, Borja

AU - Krznaric, Zeljko

AU - Magro, Fernando

AU - Karmiris, Konstantinos

AU - Raine, Tim

AU - Drobne, David

AU - Koutroubakis, Ioannis

AU - Chaparro, Maria

AU - Yanai, Henit

AU - Burisch, Johan

AU - Kopylov, Uri

PY - 2021/7/1

Y1 - 2021/7/1

N2 - Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn’s disease (CD) failing anti-Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD. Results: Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second-and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second-and VDZ as a third-class therapy (group B). At week 16–22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (p = 0.9); 41/156 (26.2%) and 15/48 (31.2%) were in clinical remission (p = 0.5). At week 52; 89/103 (86%) patients and 25/29 (86.2%) of the patients with available data had responded to third-class treatment in groups A and B, respectively (p = 0.9); 31/103 (30%) and 47/29 (24.1%) were in clinical remission (p = 0.5). Conclusion: Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent.

AB - Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn’s disease (CD) failing anti-Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and Methods: In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD. Results: Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second-and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second-and VDZ as a third-class therapy (group B). At week 16–22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (p = 0.9); 41/156 (26.2%) and 15/48 (31.2%) were in clinical remission (p = 0.5). At week 52; 89/103 (86%) patients and 25/29 (86.2%) of the patients with available data had responded to third-class treatment in groups A and B, respectively (p = 0.9); 31/103 (30%) and 47/29 (24.1%) were in clinical remission (p = 0.5). Conclusion: Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent.

KW - Anti-TNF failure

KW - Crohn’s disease

KW - Treatment failure

KW - Treatment response

KW - Ustekinumab

KW - Vedolizumab

UR - http://www.scopus.com/inward/record.url?scp=85114078800&partnerID=8YFLogxK

U2 - 10.3390/jcm10132914

DO - 10.3390/jcm10132914

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 34209880

AN - SCOPUS:85114078800

SN - 2077-0383

VL - 10

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

IS - 13

M1 - 2914

ER -

Effectiveness of third-class biologic treatment in crohn’s disease: A multi-center retrospective cohort study

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this